All Journals > Clinical Infectious Diseases > 1 January 2008 > Viral Kinetics in Hepatitis C Management

Article Tools

Search for Related Articles

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

1 January 2008

Volume 46, Number 1
Clinical Infectious Diseases 2008;46:78–84
© 2008 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2008/4601-0012$15.00
DOI: 10.1086/523585
MAJOR ARTICLE

Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C

Fred Poordad,1

K. Rajender Reddy,2 and

Paul Martin3

1Hepatology and Liver Transplantation, Cedars‐Sinai Medical Center, Los Angeles, California; 2Gastroenterology Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and 3Department of Medicine, Mount Sinai Medical Center, New York, New York

Background.Rapid virologic response (RVR), defined as an undetectable serum hepatitis C virus (HCV) RNA level at week 4 of treatment, is emerging as an important milestone in the treatment of patients who have chronic hepatitis C by use of pegylated interferon‐alfa and ribavirin—the current standard of care. This assessment is being used to individualize treatment duration, which is currently recommended as 48 weeks in patients infected with HCV genotype 1 (G1) and 24 weeks in those infected with HCV G2 or G3.

Methods.We collated information from studies including assessment of HCV RNA level at week 4, specifically highlighting the relationship between RVR and other predictors of treatment outcome and the manner in which RVR can be used to optimize treatment outcomes for specific patient groups.

Results.The role of RVR in the treatment of patients with chronic hepatitis C varies according to viral genotype. Among patients with HCV G2/G3 infection, several studies have shown that shortening the treatment duration to 12–16 weeks is effective among those who attain RVR. In contrast, RVR may be used as an indicator for both shortened and extended treatment durations among patients with HCV G1 infection. HCV G1–infected patients with low baseline viral load who attain RVR may be effectively treated for 24 weeks, whereas patients who do not attain RVR may be candidates for an extended 72‐week regimen.

Conclusions.RVR is rapidly becoming a new tool for predicting treatment outcomes in patients with chronic hepatitis C and represents a key opportunity to individualize therapy according to treatment‐related viral kinetics.

Received 26 April 2007; accepted 13 August 2007; electronically published 30 November 2007.

Reprints or correspondence: Dr. Fred Poordad, Hepatology and Liver Transplantation, Cedars‐Sinai Medical Center, Ste. 590W, 8635 W. Third St., Los Angeles, CA 90048 ().

Cited by

Emanuele Durante‐Mangoni, Rosa Zampino, Giuseppe Portella, Luigi E. Adinolfi, Riccardo Utili, and Giuseppe Ruggiero. Correlates and Prognostic Value of the First‐Phase Hepatitis C Virus RNA Kinetics during Treatment. Clinical Infectious Diseases 0:0, 000-000
Abstract-Full Text-PDF Version (268 kB)
Stefan Zeuzem. (2008) Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nature Clinical Practice Gastroenterology & Hepatology 5:11, 610-622
Online publication date: 1-Dec-2008.
CrossRef
Chen‐Hua Liu, Chun‐Jen Liu, Chih‐Lin Lin, Cheng‐Chao Liang, Shih‐Jer Hsu, Sheng‐Shun Yang, Ching‐Sheng Hsu, Tai‐Chung Tseng, Chia‐Chi Wang, Ming‐Yang Lai, Jun‐Herng Chen, Pei‐Jer Chen, Ding‐Shinn Chen, and Jia‐Horng Kao. (2008) Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. Clinical Infectious Diseases 47:10, 1260-1269
Online publication date: 15-Nov-2008.
Abstract-Full Text-PDF Version (496 kB)
J. Morello, S. Rodriguez-Novoa, I. Jimenez-Nacher, V. Soriano. (2008) Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. Journal of Antimicrobial Chemotherapy 62:6, 1174-1180
Online publication date: 10-Oct-2008.
CrossRef
Susan J Keam, Risto S Cvetković. (2008) Peginterferon-α-2a (40 kD) Plus Ribavirin. Drugs 68:9, 1273-1317
Online publication date: 1-Feb-2008.
CrossRef
Joji Toyota, Yosiyasu Karino, Jun Akaike, Takumi Ohmura, Takahiro Sato, Katu Yamazaki, Yasuaki Kuwata, Tomohiro Arakawa, Shigeyuki Furuya, Kazuhiro Matuyama, Takao Harada. (2008) Prediction of efficacy and viral kinetics using COBAS TaqMan HCV "automated" during antiviral treatment of hepatitis C. Kanzo 49:7, 297-306
Online publication date: 1-Feb-2008.
CrossRef
Back to Top
Close Popup